Introduction
Hematopoietic stem cells (HSCs) are desirable targets for gene therapy based upon their self-renewal and multilineage differentiation abilities and retroviral vectors are the most extensively employed for HSC gene therapy applications. However, gene transfer efficiency into HSCs using retroviral vectors has been disappointingly low. 1 The quiescent nature of human HSCs along with the low density of retroviral receptors on their surface has hindered the efficiency of gene transfer with retroviral vectors. 2 Much effort has been made to improve upon the gene transfer efficiency into HSCs using nonhuman primate models. 3 One promising strategy to overcome these limitations is to expand gene-modified hematopoietic cells in vivo after transplantation. Should in vivo expansion be feasible, clinically relevant gene transfer levels could theoretically be achieved even with very low initial engraftment levels of successfully genetically modified cells.
encoding the SAG and reinfused into each myeloablated monkey. Three of the six monkeys that received SAG transduced HSCs showed an increase in the levels of circulating progeny containing the provirus in vivo following administration of estrogen or tamoxifen without any serious adverse effects. In one monkey examined in detail, transduced hematopoietic progenitor cells were increased by several-fold (from 5% to 30%). Retroviral integration site analysis revealed that this observed increase was polyclonal and no outgrowth of a dominant single clonal population was observed. These results demonstrate that the inclusion of our SAG in the retroviral construct allows selective in vivo expansion of genetically modified cells by a non-toxic hormone treatment.
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To this end, several investigators have explored strategies designed to confer chemotherapeutic drug resistance to HSCs by the introduction of the multidrug resistance (MDR)-1 gene allowing selection and expansion of transduced HSCs in vivo after transplantation by administration of an MDR-pumped drug, such as taxol. [4] [5] [6] [7] [8] Although in vivo selection of transduced cells with the MDR-1 gene appeared feasible in mice, 4 it has been difficult to document such selection in nonhuman primates or humans. [5] [6] [7] [8] In vivo selection with the MDR-1 gene may have resulted from selection at the level of relatively mature precursor cells, not at the level of HSCs, since HSCs express the MDR-1 gene. [9] [10] [11] In addition, aberrant splicing of the vector-derived MDR-1 transcript has been shown in human hematopoietic cells, which lead to the generation of nonfunctional, truncated MDR-1 gene product. 12 Furthermore, mice transplanted with ex vivo expanded MDR1-transduced HSCs developed a myeloproliferative disorder, raising concerns about this approach and questioning the nature of the selection observed in earlier studies. 13 Several alternative drug resistance genes have been studied in vitro, including O 6 -alkylguanine-DNA-alkyltransferase, which confers protection to some alkylating agents 14, 15 and mutant dihydrofolate reductase. 16, 17 Although the strategy using the mutant dihydrofolate reductase has proven feasible in vivo in mice, 17 confirmatory studies in nonhuman primates or humans have not yet been reported.
An alternative strategy for in vivo expansion of transduced cells is to confer a direct proliferative advantage to the gene-modified cells relative to their nontransduced counterparts. Some groups developed selective amplifier genes or cell growth switches, which are chimeric genes expressing a fusion protein composed of a growth factor receptor signaling domain and its specific molecular switch. 18, 19 Blau et al developed cell growth switches that are cytokine receptor-FK506 binding protein (FKBP) fusion genes to confer inducible proliferation to transduced cells. 19, 20 In their system, cytokine receptor signaling is turned on by treatment with a synthetic dimerizer FK1012 or its derivatives. Although the original FK1012 is complicated by its potential interactions with endogenous FKBPs leading to immunosuppression of recipients, its derivatives (AP1903, AP20187 etc) have been designed to reduce this interaction. 21 Successful in vivo expansion of gene-modified hematopoietic cells was obtained using the cell growth switch composed of the intracellular part of Mpl and FKBP in a murine model. 22 We previously developed a chimeric selective amplifier gene (SAG) composed of the signalling domain of the granulocyte colony-stimulating factor (G-CSF) receptor and the estrogen receptor hormone-binding domain, and demonstrated that primary bone marrow progenitor cells transduced with the SAG could be expanded in response to estrogen or tamoxifen in vitro. 18, 23, 24 The estrogen receptor-mediated dimerization of the chimeric gene product is assumed to be critical for the activation of the G-CSF receptor signaling. 25 We have further shown that in vivo expansion of transduced cells with the SAG is feasible in a murine transplantation model. 26 Adaptation of this in vivo selection system for use in nonhuman primates should determine its clinical feasibility. In this study, we evaluated efficacy of the SAG in the setting of a clinically applicable nonhuman primate (cynomolgus monkey) transplantation protocol.
Results

Construct of retroviral vectors
The selective amplifier gene (SAG) is a chimeric gene composed of the G-CSF receptor gene and the estrogen receptor gene hormone-binding domain (Figure 1 ). 18 To abolish responsiveness to G-CSF, the G-CSF-binding domain was deleted from the chimeric gene. Thus, G-CSF signaling can be generated by treatment with estrogen, but no longer with G-CSF. The G-CSF receptor transmits two signals; proliferation and differentiation. The differentiation signal was undesirable for the purpose of expansion of transduced cells. To abolish the differentiation signal, tyrosine 703 was replaced by phenylalanine (Y703F), as this residue is reported to be involved in the differentiation signaling. 27 We previously demonstrated that this SAG (estrogen-responsive SAG, or designated GCRER) product predominantly transmits a proliferation signal by treatment with estrogen in vitro. 23 We constructed a further modified SAG in which a point mutation (G525R) was introduced into the estrogen receptor moiety of the GCRER (Figure 1) . 24, 28 This SAG product (tamoxifen-responsive SAG, or designated GCRTmR) no longer reacts to endogenous estrogen but reacts to synthetic hormones such as tamoxifen (Tm). 24 To facilitate monitoring in vivo, we constructed a bicistronic retroviral vector expressing both GCRER (as the first cistron) and green fluorescent protein (GFP; as the second cistron) (Figure 1 ). The internal ribosome entry site (IRES) enables coordinated expression of both genes. 29 Retroviral vectors expressing only GCRER, GCRTmR, or GFP were also constructed ( Figure 1 ). 24 Additionally, we prepared control, non-expressing retroviral vectors (G1PLI and G1PLII) which contain nontranslated sequences from the neomycin resistance and ␤-galactosidase genes by disrupting the first ATG codons. 30 Single marking study To increase the likelihood of primitive hematopoietic cell cycling and thus retroviral transduction, stem cell factor (SCF) and G-CSF were administered to the animals before bone marrow harvesting. 31 Furthermore, this strategy could allow CD34 Ϫ HSCs, if any, to convert to CD34 + HSCs, thus increasing the number of HSCs included in the CD34 + -cell fraction. 32 Bone marrow CD34 + cells were harvested from four cynomolgus monkeys primed with these cytokines. As summarized in Table 1, CD34 + cells were transduced with a retroviral vector expressing only GFP in two monkeys (C1 and C2) or with a retroviral vector expressing both SAG and GFP (GCRER/GFP) in the other two monkeys (S1 and S2). The transductions were performed for 4 days in the presence of multiple cytokines including Flt-3 ligand and RetroNectin. 33, 34 Following ex vivo transduction, gene transfer efficiency was assessed by semiquantitative PCR performed on the end transduction product or by PCR of individual clonogenic progenitors (colony forming units, CFU) derived from the sample. Thirteen to 40% of cells contained the provirus, and 10 to 70% of colonies formed by the cells contained the provirus (Table 1 ). There was little correlation between transduction efficiency estimated by the two methods, yet this observation has been repeatedly reported in nonhuman primate models. 33 The transduced cells were infused into each animal after myeloablative conditioning by total body irradiation.
The presence of the GFP gene within the vector construct allows assessment of transgene expression by fluorescence among peripheral blood cells and bone marrow-derived clonogenic colonies after transplantation. However, few peripheral blood cells fluoresced and bone marrow-derived colonies fluoresced at very low levels. Several explanations for such poor transgene expression have been offered previously including transgene silencing 35 and poor expression of the second cistron in a bicistronic vector, 36 the position of the GFP gene in our construct. To avoid complicating the analysis of the gene transfer efficiency by assessment of the GFP expression, we defined gene transfer efficiency as the percentage of provirus-containing cells. We examined the provirus in peripheral blood and bone marrow-derived CFU by PCR after transplantation.
In the two monkeys transplanted without the SAG (C1 and C2), around 5-10% of CFU contained the provirus for more than 1 year after transplantation (data not shown). In one female recipient of cells transduced with the estrogen-responsive SAG (S1), although only 10% of CFU contained the provirus in the ex vivo transduced cell population (Table 1) , nearly half of bone marrow-derived CFU contained the provirus just after transplantation without administration of estrogen ( Figure 2 ). Some transduced cells presumably reacted to endogenous estrogen or estrogen-like substances. Six months after transplantation, the transduced fraction dropped to 5%, at which point estrogen administration was initiated. Following estrogen administration, the percentage of CFU containing the transgene increased up to 30% (Figure 2) . A lineage preference for myeloid over erythroid colony formation was not observed in the presence of the SAG that generated the G-CSF receptor-mediated proliferation signal in the cells. Peripheral blood cells containing the SAG vector sequence also increased from Ͻ0.1% to~1% (data not shown) in response to estrogen administration. Estrogen-responsiveness was not demonstrable in the second animal (S2) as the fraction of CFU containing the SAG sequence was not increased following estrogen administration (data not shown). The development of an estrogen-related thoracic deformation precluded subsequent estrogen administration.
Figure 1 Vector construction. The GCRER is a prototype of the selective amplifier gene (SAG) and is composed of the G-CSF receptor (GCR) gene and the estrogen receptor (ER) gene hormone-binding domain (HBD). In the GCRER, the G-CSF-binding domain (amino acids 5-195) was deleted from the GCR gene to abolish responsiveness to G-CSF, and a point mutation (Y703F) was introduced to knock out the differentiation signal generated by the GCR. In the GCRTmR, another point mutation (G525R) was introduced into the ER gene moiety of the GCRER. GCRTmR no longer reacts to endogenous estrogen, but responds to tamoxifen. The GCRER/GFP vector is a bicistronic vector expressing the GCRER gene (as the first cistron) and GFP gene (as the second cistron). A vector expressing only the GCRER, GCRTmR, or GFP gene was also constructed. All vectors are derived from the mouse stem cell virus (MSCV) and pseudotyped with the gibbon ape leukemia virus envelope. TM, trans-membrane domain; TA, transactivating domain; IRES, internal ribosome entry site; LTR, long terminal repeat.
+ CFU b cells a Control study C1 (female) GFP 20 ND (-) N A N A N A -------------------------------------------------------------------------------------------------------------------------------------------------------------- C2 (female) GFP 13 70 (-) N A N A N A ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Single marking S1 (female) GCRER/GFP 37 10 Estradiol Pellet 390 study implantation --------------------------------------------------------------------------------------------------------------------------------------------------------------- S2 (female) GCRER/GFP 40 27 Estradiol Intramuscular 900 → injection ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Dual marking GCRER 1 2.6 study D1 (female) ----------------------------------------------------- Toremifene Oral intake 130 --------------- Nonexpressing PL II 3 8.6 → -------------------------------------------------------------------------------------------------------------------------------------------------------------- GCRTmR 4.7 8.3 D2 (male) ----------------------------------------------------- Toremifene Oral intake 1600 --------------- Nonexpressing PL II 1.6 2.2 → -------------------------------------------------------------------------------------------------------------------------------------------------------------- GCRTmR 19 38.5 → D3 (male) -----------------------------------------------------Hydroxytamoxifen Oral intake 70 --------------- Nonexpressing PL I 42 34.0 → -------------------------------------------------------------------------------------------------------------------------------------------------------------- GCRTmR 46 24.4 → D4 (male) -----------------------------------------------------Hydroxytamoxifen Oral intake 80 ---------------
Dual marking study
Dual genetic marking was subsequently employed to compare the effect of the SAG vectors to non-SAG vectors within, rather than between, individual animals. From four monkeys (D1-4), cytokine-primed bone marrow CD34 + cells were harvested and split into two equal aliquots. One aliquot was transduced with an SAG-vector and the other with a control, non-expressing vector (Table 1) . Both aliquots were reinfused simultaneously into each animal following myeloablative conditioning. The animals received toremifene (a derivative of tamoxifen; D1 and D2) 37 or hydroxytamoxifen (an active metabolite of tamoxifen; D3 and D4) after transplantation and in vivo marking levels derived from the two populations were examined and compared by PCR.
The results of two monkeys (D1 and D2) which
Figure 2 In vivo expansion of transduced hematopoietic progenitor cells in animal S1. CD34 + cells from the animal S1 were transduced with a retroviral vector expressing the estrogen-responsive SAG (GCRER). The transduced cells were reinfused into the monkey that was myeloablated by total body irradiation. After transplantation, individual bone marrowderived colonies were examined for the provirus by PCR. The percentage of the provirus-containing cells is shown over time (months) after transplantation. The arrows indicate time-points of subcutaneous implantation of estradiol (E2) pellets.
received toremifene are shown in Figure 3 . In both monkeys, peripheral blood cells containing the SAG were increased by one log in response to the toremifene administration (from Ͻ0.1% to~1%), although cells containing the non-expressing vectors remained at stable levels. The increase in SAG-containing peripheral blood cells was transient. The accidental death of animal D1 precluded further follow-up data. On the other hand, in animal D2, the fraction of SAG-containing cells returned to the original levels after discontinuing the toremifene administration. Bone marrow-derived CFU were also examined in these two monkeys. Since the ex vivo transduction levels were very low in these two monkeys (Table 1) , there were no provirus-positive CFU derived from bone marrow after transplantation. However, following administration of toremifene, a fraction of the CFU (2-3%) became positive for the SAG-provirus in each monkey, although there were still no CFU containing the control vector sequence (data not shown). Selective expansion was not observed in the other two monkeys that received hydroxytamoxifen (D3 and D4), yet the serum concentrations of hydroxytamoxifen did not reach the biologically optimal levels (at least 100 nM). 24 Serious adverse effects were not observed in the animals after drug treatment, but there were some symptoms associated with high-dose administration of estradiol. Monkeys receiving estradiol (S1 and S2) showed genital swelling. One monkey (S2) showed abnormal osteogenesis resulting in thoracic deformation and further drug administration was discontinued.
Clonal integration analysis
Unique vector insertion sites in individual CFU in animal S1 were identified using the inverse PCR technique. 38, 39 DNA from 48 provirus-positive colonies at the first peak of increase in transduced cells (1 and 2 months posttransplantation; Figure 2 ) and from 54 provirus-positive colonies at the second peak (10 and 11 months posttransplantation) in the animal S1 were analyzed. Thirtyfive colonies yielded distinct bands on inverse PCR (Figure 4a) , and amplified DNA segments were sequenced. Overall, 14 unique flanking genomic sequences were identified at four time-points (1, 2, 10 and 11 months post-transplantation) ( Table 2) . At least seven clones contributed to the first peak and nine to the second peak, clearly indicating no outgrowth of a single clonal population (Figure 4b) . Two of the clones were common sequences at intervals of 10 months, suggesting that true HSCs were transduced.
Discussion
The ability to selectively amplify cells containing potentially therapeutic genes in vivo would represent an important tool for the clinical application of HSC-based gene transfer, circumventing many of the current limitations of this promising technology. We have examined the feasibility of such selection using a chimeric selective amplifier gene (SAG) in vivo in nonhuman primates. In the setting of a cynomolgus monkey transplantation protocol, levels of 30-50% of gene-modified CFU were reached in vivo when the SAG was used. These very high gene marking levels were attainable despite low initial marking levels. Although one may claim that this may be potentially due to technical issues, for instance, cross- colony contamination, the use of individual, well-separated CFU ensured analysis at the single cell level. The use of individual colonies indeed allowed clonal integration site analysis, and such analysis conducted in animal S1 suggested that the increase of in vivo marking was not an outgrowth of a single clonal population, but that multiple clones contributed to the increase of transduced cells. The unique insertions identified also ruled out cross contamination as an explanation of the high level marking observed. The clones detected at the second peak around 10 and 11 months after transplantation were likely derived from transduced, true long-term repopulating HSCs and their progeny may have expanded in response to the administered estrogen. Increased marking derived from multiple transduced clones in response to estrogen administration is encouraging for future applications of the SAG.
This in vivo expansion method may also circumvent other problems of HSC gene therapy. One is the perceived necessity for myeloablation of recipients, which is associated with high systemic toxicity or potential damage to marrow stroma. 1 Even with nonmyeloablative conditioning, successful engraftment of transduced cells even at low levels may allow expansion to clinically relevant levels with this method. [40] [41] [42] Another problem is decline of transgene expression in vivo. 35, 43 Since cells to be expanded in this system require transgene (SAG) expression, only cells expressing the transgene can be expanded, thus circumventing transgene silencing.
A highly stable and specific molecular switch is required to strictly regulate the cytokine receptor signal of SAGs, or a safety concern about leukemogenesis may be raised. Our chimeric gene product, either estrogen-or tamoxifen-responsive, can only be activated by a synthetic steroid metabolite with high stability and specificity such as tamoxifen. 28 Furthermore, a safety modifiGene Therapy cation has been made to enhance the specificity of the molecular switch in the tamoxifen-responsive SAG (GCRTmR) compared with its prototype estrogenresponsive SAG (GCRER). In the tamoxifen-responsive SAG, a point mutation (G525R) was introduced into the estrogen receptor moiety so that the molecular switch no longer responds to endogenous estrogen, thus minimizing the background signal transduction generated by endogenous estrogen. 24 Until now, no leukemogenesis has been observed even in the monkeys (S1, S2 and D1) which received the prototype estrogen-responsive SAG (GCRER). Thus, leukemogenesis may be regarded as an unlikely event.
The observations obtained from the current study suggest that the increase of transduced cells with the SAG was transient. Our present method may not result in expansion of transduced cells at the level of HSCs. It is possible that the LTR promoter does not express the SAG in HSCs. Alternatively, the G-CSF receptor signal generated by the SAG may not induce proliferation of HSCs. 44 Thus, the expansion of transduced cells might occur only within the differentiated progeny of transduced HSCs, not at the level of transduced HSCs themselves. However, even if the effect is transient, therapeutic effects can result from a transient increase of transduced cells in certain diseases, such as chronic granulomatous disease, or tamoxifen can be administered repeatedly over time to maintain clinically relevant effects.
The levels of transduced cells in peripheral blood were much lower than the levels of transduced progenitor cells in bone marrow. As shown in the monkey S1, significant fractions (10% or more) of bone marrow-derived CFU contained the provirus for more than 1 year after transplantation (Figure 2) , indicating successful transduction of long-term repopulating HSCs. Nonetheless, very few provirus-containing cells were detected in peripheral Table 2 ). Overall 14 unique flanking genomic sequences were found at four time-points (1, 2, 10 and 11 months after transplantation). At least seven clones contributed to the first peak and nine clones contributed to the second peak, clearly indicating no outgrowth of a single clonal population. Two of the clones were common sequences at intervals of 10 months.
Table 2
Genomic DNA sequences flanking the LTR in animal S1 45 In the present study, half of six monkeys that received the SAG-transduced HSCs showed an increase of transduced cells in vivo ( Table 1 ), suggesting that responses to exogenous estrogen may vary among monkeys. Little response in monkeys D3 and D4 may be explained by the low serum drug (hydroxytamoxifen) concentrations obtained. Although, in the other monkey S2, the serum drug concentrations reached biologically optimal levels (>100 nM), an increase of transduced cells was not observed. We consider that a more potent SAG would be required to achieve in vivo expansion in all monkeys. We are currently testing further modified SAGs with the thrombopoietin receptor (Mpl) as a growth signal generator instead of the G-CSF receptor to overcome variable responses among monkeys.
20,44
Materials and methods
Cells and animals
All cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Herndon, VA, USA) sup-plemented with 10% fetal calf serum (FCS; Gibco, Gaithersburg, MD, USA) and antibiotics (100 U/ml penicillin, Banyu, Tokyo, Japan and 0.1 mg/ml streptomycin, Meiji, Tokyo, Japan). Young cynomolgus macaques (Macaca fascicularis), weighing around 3 kg, were housed and handled in accordance with the Rules for Care and Management at the Tsukuba Primate Center and with the Guiding Principles for Animal Experiments using NonHuman Primates formulated by the Primate Society of Japan. The protocol of the experimental procedures was approved by the Animal Welfare and Animal Care Committee of the National Institute of Infectious Diseases (Tokyo, Japan).
Vector construction
Construction of two selective amplifier genes (SAGs), GCRER and GCRTmR cDNAs, were previously described. 23, 24 The GCRER cDNA is a prototype SAG composed of two genes: (1) the murine G-CSF receptor (GCR) gene with deletion of the ligand-binding domain (amino acids 5-195 of the GCR) and with a point mutation (Y703F) to abolish the differentiation signal generated by the GCR; 27 and (2) the gene encoding the rat estrogen receptor (ER) hormone-binding domain (HBD). 23 The GCRTmR cDNA is a modified SAG. In the GCRTmR, a point mutation (G525R) was introduced into the ER gene moiety of the GCRER to abolish responsiveness to endogenous estrogen, but retain responsiveness to synthetic hormones such as tamoxifen (Tm). 24, 28 Four mouse stem cell virus (MSCV)-based vector plasmids expressing the enhanced green fluorescent protein (designated simply GFP in this article; Clontech, Palo Alto, CA, USA), expressing GCRER, expressing GCRTmR, and expressing both GCRER and GFP (GCRER/GFP) were constructed as described elsewhere (Figure 1) . 23, 24 These vector plasmids were transfected into the BOSC23 ecotropic packaging cell line by the calcium phosphate method as previously described. 46 Supernatants were harvested 48-60 h after transfection and were used to infect PG13 packaging cells using standard techniques 47 to generate retroviruses pseudotyped with the gibbon ape leukemia virus envelope. Stable producer clones were established by limiting dilution. The titers of GFP, GCRER, GCRTmR and GCRER/GFP vectors used in these studies were 1 × 10 6 , 5 × 10 5 , 5 × 10 5 , and 5 × 10 5 /ml, respectively, as assessed by viral RNA dot-blot according to the method described elsewhere. 47 Two nonexpressing retroviral vectors G1PLI and G1PLII were previously described. 30 Both supernatants of G1PLI and G1PLII used in this study had titers of 5 × 10 5 /ml as assessed by viral RNA dot-blot.
Transduction and transplantation
Animals were treated with recombinant human SCF (50 or 200g/kg; Amgen, Thousand Oaks, CA, USA) and recombinant human G-CSF (10, 50, or 100g/kg; Chugai, Tokyo, Japan) subcutaneously daily for 5 days, immediately followed by 50 ml bone marrow aspiration. The nucleated cell fraction was obtained by red blood cell lysis with ACK buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM EDTA; Wako, Osaka, Japan). Enrichment for CD34
+ cells was performed using the immunomagnetic beads (Dynal, Lake Success, NY, USA). The purity of CD34 + cells obtained using this technique ranged from
Gene Therapy 90 to 95% as assessed with another monoclonal anti-CD34 antibody (clone 563; PharMingen, San Diego, CA, USA). Mean CFU enrichment was 48-fold as assessed by colonyforming progenitor assays performed before and after enrichment. Transduction was conducted for a total of 96 h at a starting density of 1-5 × 10 5 cells/ml with daily replacement of vector supernatants and cytokines. Transduction cultures were supplemented with 50 ng/ml recombinant human interleukin-6 (IL-6; Ajinomoto, Osaka, Japan), 100 ng/ml recombinant human thrombopoietin (Kirin, Tokyo, Japan), 100 ng/ml recombinant human SCF (Amgen), and 100 ng/ml recombinant human Flt-3 ligand (FL; Research Diagnostics, Flanders, NJ, USA). However, in the initial two monkeys (C1 and C2), 20 ng/ml recombinant human interleukin-3 (IL-3; Kirin) was included in the transduction cultures. Thrombopoietin was not included in the transduction cultures for the initial three monkeys (C1, C2, and S1). RetroNectin (Takara, Shiga, Japan) was used to coat culture plates before transduction and was used as directed. 48 After the 96-h transduction period, transduced cells were washed and resuspended in phosphate-buffered saline (PBS) containing 10% autologous serum, and reinfused into each monkey following 500 cGy (all monkeys except S2) or 550 cGy (S2) total body irradiation daily for the preceding 2 days.
Estrogen or tamoxifen administration
In the monkey S1, estradiol (E2) pellets (17-␤-estradiol 0.2 g/pellet, release time 60 days; Innovative Research of America, Sarasota, FL, USA) were implanted twice subcutaneously (0.2 g/body at day 231 and another 2 g/body at day 287 after transplantation). Weekly intramuscular injection of E2 was administered to monkey S2 (50 mg/body once a week starting from day 47 to day 68 after transplantation). Daily oral administration of toremifene (a derivative of tamoxifen, Nippon Kayaku, Tokyo, Japan) 37 was administered to monkeys D1 (0.02 mg/body/day at days 88-94, 0.2 mg/body/day at days 95-101, 2 mg/body/day at days 102-108, and 20 mg/body/day at days 109-115 after transplantation) and D2 (100 mg/body/day from day 63 to day 108 after transplantation). The dose escalation of toremifene in the animal D1 was conducted to elucidate the appropriate dose of administration to monkeys and it was found that at least 20 mg/body/day was necessary to achieve the biologically optimal serum concentrations (>100 nM) of toremifene. Daily oral administration of hydroxytamoxifen (an active metabolite of tamoxifen; Sigma, St Louis, MO, USA) was administered to monkeys D3 (10 mg/body/day starting from day 39 to day 78 after transplantation) and D4 (10 mg/body/day starting from day 32 to day 59 after transplantation). Serum concentrations of E2 were measured by an ELISA kit (IMx Estradiol kit, Abbott Laboratory, Abbott Park, IL, USA) as directed. Serum concentrations of toremifene and hydroxytamoxifen were measured by hyperperformance liquid chromatography (HPLC) (NAC, Tokyo, Japan).
Colony assays and PCR
Cells were plated in ␣-minimum essential medium (MEM, Gibco) containing 1.2% methylcellulose (Shinetsu Kagaku, Tokyo, Japan) supplemented with 2 U/ml recombinant human erythropoietin (EPO; Roche Diagnostics, Mannheim, Germany), 100 ng/ml recombinant human IL-3 (PeproTech, London, UK), 100 ng/ml interleukin-11 (IL-11; PeproTech), 100 ng/ml recombinant human SCF (Biosource, Camarillo, CA, USA), 20% FCS (Intergen, Purchase, NY, USA), 1% bovine serum albumin (Sigma), 5 × 10 Ϫ5 M 2-mercaptethanol (Sigma), and antibiotics (100 U/ml penicillin and 0.1 mg/ml streptomycin). At day 14, colonies containing greater than 50 cells were counted, and individual colonies were plucked into 50l of distilled water, digested with 20g/ml proteinase K (Takara) at 55°C for 1 h followed by 99°C for 10 min, and assessed for vector (GFP, SAG, or non-expressing vector) sequence by nested PCR. The outer primer set was 5'-GCC ACA AGT TCA GCG TGT CC-3' and 5'-AGC TCG ATG CGG TTC ACC AG-3' for GFP-expressing vectors, 5'-GTA CAT TCG CTC TGA CTC CAC TCA G-3' and 5'-CAA TAA GCC CAT CAT TGA GGC TTC AC-3' for SAG-expressing vectors, and 5'-TCC ATC ATG GCT GAT GCA ATG CGG C-3' and 5'-GAT AGA AGG CGA TGC GCT GCG AAT CG-3' for non-expressing vectors. Amplification conditions for outer PCR were 95°C for 1 min, 54°C for 1 min, and 72°C for 2 min with 20 cycles. The outer PCR products were purified by the MicroSpin S-400 HR Columns (Amersham, Piscataway, NJ, USA). The inner primer set was 5'-TAC GGC AAG CTG ACC CTG AAG-3' and 5'-TGT CGC CCT CGA ACT TCA CCT-3' for GFP-expressing vectors, 5'-CCA CCC CTA GCC CTA AAT CTT ATG-3' and 5'-GGT GGT TCA GCA TCC AAT AAG G-3' for SAG-expressing vectors, and 5'-ATA CGC TTG ATC CGG CTA CCT G-3' and 5'-GAT ACC GTA AAG CAC GAG GAA G-3' for non-expressing vectors. Amplification conditions for inner PCR were 95°C for 1 min, 54°C for 1 min, and 72°C for 2 min with 20 cycles. Simultaneous PCR for ␤-actin sequence was also performed to document DNA amplification of the sample on each colony. The primer set for ␤-actin was 5'-CAT TGT CAT GGA CTC TGG CGA CGG-3' and 5'-CAT CTC CTG CTC GAA GTC TAG GGC-3'. Amplification conditions for ␤-actin PCR were 95°C for 1 min, 54°C for 1 min, and 72°C for 2 min with 30 cycles. The sizes of the final PCR products were 246, 315, 370 and 234 bp for GFP, SAG, nonexpressing vector, and ␤-actin sequences, respectively. PCR products were separated on 1% agarose gels. The transduction efficiency of CFU was calculated by dividing the number of positive colonies for vector sequence by the number of positive colonies for ␤-actin sequence.
Semi-quantitative PCR
Heparinized peripheral blood was drawn from each monkey at the indicated times. Nucleated cells were obtained by ACK lysis of red blood cells. Cellular DNA was extracted by the QIAamp Blood Kit (Qiagen, Valencia, CA, USA) and 250 ng of DNA was used for each PCR. The standards consisted of DNA extracted from the GCRER/GFP-vector producer clone (which has two copies of the vector sequence per cell) or the G1PLII-vector producer clone (which has three copies of the vector sequence per cell) serially diluted with control cynomolgus genomic DNA. The negative control consisted of DNA extracted from nontransduced cynomolgus peripheral blood. Simultaneous PCR for ␤-actin sequence was also performed to document initial DNA amounts of samples. PCR for vector (GFP, SAG, or non-expressing vector) sequence was performed in a nested way using the same primers as described in the above section 'Colony assays and PCR', but the inner PCR was carried out in the presence of SYBR Green using an ABI PRISM 7700 sequence detection system with the buffers, nucleotides, and Taq polymerase from the SYBR Green PCR Core Reagents Kit (PE Applied Biosystems, Foster City, CA, USA) as directed. Amplification of the inner PCR was carried out using a two-step PCR method with a denaturing temperature of 95°C and an annealing temperature of 60°C. All semi-quantitative PCR was certified each time to yield linear amplifications in the range of the intensity of the positive control series (0.0001~1.0 copy/cell, correlation coefficient >0.98). For calculating the transduction efficiencies, the Ct value of the vector sequence was normalized based on the Ct value of the internal control ␤-actin sequence on the same sample as directed in the manufacturer's protocol.
Clonal integration analysis
Individual colony DNA extracted as described in 'Colony assays and PCR' was resuspended in 200 l PBS and mixed with 200 l buffered phenol-chloroform-isoamyl alcohol (25:24:1; vol/vol). The aqueous phase was precipitated by the addition of 2 g glycogen (Boehringer Mannheim, Mannheim, Germany), 18 l of 10 mol/l ammonium acetate, and 500 l absolute ethanol, and this was incubated at -20°C overnight. DNA was centrifuged at 10 000 r.p.m. for 20 min, rinsed in 70% ethanol, and dried on the bench-top for 1 h. DNA pellets were resuspended in 25 l H 2 O.
The clonal identity of vector proviral integrants was determined using inverse PCR by the method previously described. 39 To 20 l DNA from each sample, 10 l React 2 Buffer (Gibco), and 2 l (20 U) TaqI restriction enzyme (Gibco) was added with H 2 O to a total volume 100 l. Samples were digested for 2 h at 65°C with the readdition of 2 l of TaqI after the first hour of incubation. A 16-l sample was then ligated by the addition of 4 l 5 × T4 ligase buffer (Gibco) and 1 l T4 ligase (Gibco) at 16°C for a minimum of 6 h. The first round of amplification of 10-l circularized DNA used the primers 5'-AGG AAC TGC TTA CCA CA and 5'-CTG TTC CTT GGG AGG GT in Perkin-Elmer (Foster City, CA, USA) PCR buffer. The first cycle was at 95°C denaturation for 5 min, 50°C annealing for 2 min, and 72°C extension for 4 min. The subsequent 29 cycles were identical, except that the denaturation time was reduced to 1 min. Nested PCR was then performed on 2 l of the amplified product with primers 5'-TCC TGA CCT TGA TCT GA and 5'-CTG AGT GAT TGA CTA CC using the same reaction condition and cycles. Resultant PCR products were separated on a 1% agarose gel with ethidium bromide. Bands were purified from the agarose gel and subjected to DNA sequence analysis. Amplified PCR products were ligated directly into the TA vector (Invitrogen, Carlsbad, CA, USA) and sequenced using an automated sequencer and Taq polymerase (Perkin-Elmer). Sequences were aligned using DNAStar (DNAStar, Madison, WI, USA).
